MindBio Therapeutics Publishes Sleep Research in Translational Psychiatry

MindBio Therapeutics Corp., a Vancouver-based biopharmaceutical company, announced that its sleep research has been published in the renowned scientific journal, Translational Psychiatry. The research highlights the effects of MB22001, MindBio’s microdosing treatment, which reportedly enhances the duration and quality of sleep after administration.

The study found that MB22001, involving sub-hallucinogenic doses of a psychedelic drug, led to an average of 24 additional minutes of sleep and 8 more minutes of REM sleep. These outcomes are significant against a backdrop where sleep has been identified as crucial for mental and physical well-being, particularly in individuals with depressive disorders.

With this published research, MindBio seeks to establish MB22001 not only as an innovative treatment for depression but also as a productive intervention against poor sleep, which is frequently associated with depressive conditions. According to the company, their treatment represents a scalable, low-side effect alternative to traditional antidepressants.

The announcement coincided with ongoing Phase 2 clinical trials and reflects MindBio’s broader strategy to target both mental health conditions and their related symptoms on a global scale. CEO Justin Hanka emphasized the potential of MB22001 to redefine treatment approaches for depression and related mood disorders.